118 related articles for article (PubMed ID: 38007757)
1. Oxaliplatin and Checkpoint Inhibitor Induces Immunogenic Cells Death and Promotes Therapeutic Efficacy in the Model of Murine Triple Positive Breast Cancer.
Shi H
Stud Health Technol Inform; 2023 Nov; 308():329-340. PubMed ID: 38007757
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Efficacy of Oxaliplatin and Pembrolizumab Combination Treatment for Triple-Negative Breast Cancer.
Chu SL
Stud Health Technol Inform; 2023 Nov; 308():341-350. PubMed ID: 38007758
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Oxaliplatin on the Immunogenic Cell Death and Cell Apoptosis of Human Merkel Cell Cancerous Tumor.
Zhang B
Stud Health Technol Inform; 2023 Nov; 308():437-444. PubMed ID: 38007770
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma.
Sun F; Cui L; Li T; Chen S; Song J; Li D
J Recept Signal Transduct Res; 2019 Jun; 39(3):208-214. PubMed ID: 31441696
[No Abstract] [Full Text] [Related]
5. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
[TBL] [Abstract][Full Text] [Related]
6. The Ability of Clinically Relevant Chemotherapeutics to Induce Immunogenic Cell Death in Squamous Cell Carcinoma.
He Z; Jing X; Dai X; Bao L; Yang X; Xiong Y; Li M
Front Biosci (Landmark Ed); 2024 Apr; 29(4):158. PubMed ID: 38682206
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
[TBL] [Abstract][Full Text] [Related]
8. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
Limagne E; Thibaudin M; Nuttin L; Spill A; Derangère V; Fumet JD; Amellal N; Peranzoni E; Cattan V; Ghiringhelli F
Cancer Immunol Res; 2019 Dec; 7(12):1958-1969. PubMed ID: 31611243
[TBL] [Abstract][Full Text] [Related]
9. NIR-II light evokes DNA cross-linking for chemotherapy and immunogenic cell death.
Huang Y; Wei D; Wang B; Tang D; Cheng A; Xiao S; Yu Y; Huang W
Acta Biomater; 2023 Apr; 160():198-210. PubMed ID: 36792048
[TBL] [Abstract][Full Text] [Related]
10. Chromomycin A
Florêncio KGD; Edson EA; Fernandes KSDS; Luiz JPM; Pinto FDCL; Pessoa ODL; Cunha FQ; Machado-Neto JA; Wilke DV
Front Immunol; 2022; 13():941757. PubMed ID: 36439184
[TBL] [Abstract][Full Text] [Related]
11. PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells.
Calvillo-Rodríguez KM; Mendoza-Reveles R; Gómez-Morales L; Uscanga-Palomeque AC; Karoyan P; Martínez-Torres AC; Rodríguez-Padilla C
Oncoimmunology; 2022; 11(1):2054305. PubMed ID: 35402082
[TBL] [Abstract][Full Text] [Related]
12. Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram.
Sun T; Yang W; Toprani SM; Guo W; He L; DeLeo AB; Ferrone S; Zhang G; Wang E; Lin Z; Hu P; Wang X
Cell Commun Signal; 2020 Mar; 18(1):36. PubMed ID: 32138738
[TBL] [Abstract][Full Text] [Related]
13. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
14. Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy.
Demontoux L; Derangère V; Pilot T; Thinselin C; Chevriaux A; Chalmin F; Bouyer F; Ghiringhelli F; Rébé C
Int J Cancer; 2019 Dec; 145(11):3101-3111. PubMed ID: 31344262
[TBL] [Abstract][Full Text] [Related]
15. Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK/elF2α/ATF4/CHOP pathway in breast cancer.
Li X; Zheng J; Chen S; Meng FD; Ning J; Sun SL
Cell Death Dis; 2021 Mar; 12(4):314. PubMed ID: 33762577
[TBL] [Abstract][Full Text] [Related]
16. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
Li Y; Zhang H; Li Q; Zou P; Huang X; Wu C; Tan L
Cancer Lett; 2020 Dec; 495():12-21. PubMed ID: 32941949
[TBL] [Abstract][Full Text] [Related]
17. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
[TBL] [Abstract][Full Text] [Related]
18. Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.
Andreidesz K; Koszegi B; Kovacs D; Bagone Vantus V; Gallyas F; Kovacs K
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669671
[TBL] [Abstract][Full Text] [Related]
19. STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells.
Jafari S; Lavasanifar A; Hejazi MS; Maleki-Dizaji N; Mesgari M; Molavi O
Daru; 2020 Jun; 28(1):159-169. PubMed ID: 31942696
[TBL] [Abstract][Full Text] [Related]
20. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
